Vaccines Unit, Preventive Medicine and Public Health Department, Vital Álvarez-Buylla Hospital, Health Care Service of Asturias, Mieres, Spain.
WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.
Euro Surveill. 2021 Mar;26(10). doi: 10.2807/1560-7917.ES.2021.26.10.2100193.
Monitoring adverse reactions following immunisation is essential, particularly for new vaccines such as those against COVID-19. We describe 20 cases of acute onset of a single supraclavicular lymphadenopathy manifesting between 24 h and 9 days after ipsilateral intramuscular administration of an mRNA-based COVID-19 vaccine, referred to our WHO Collaborating Centre for Vaccine Safety. Our results indicate that the swelling of supraclavicular lymph nodes following immunisation may constitute a benign and self-limited condition, related to a higher than recommended injection site.
监测免疫接种后的不良反应至关重要，特别是对于新型疫苗，如针对 COVID-19 的疫苗。我们描述了 20 例急性单侧锁骨上淋巴结肿大的病例，这些病例在同侧肌内注射基于 mRNA 的 COVID-19 疫苗后 24 小时至 9 天内出现，这些病例被转介至我们的世界卫生组织疫苗安全合作中心。我们的结果表明，接种疫苗后锁骨上淋巴结肿胀可能是一种良性且自限性的疾病，与高于推荐的注射部位有关。
